These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 26698536)

  • 1. Pyridazinone derivatives displaying highly potent and selective inhibitory activities against c-Met tyrosine kinase.
    Liu Y; Jin S; Peng X; Lu D; Zeng L; Sun Y; Ai J; Geng M; Hu Y
    Eur J Med Chem; 2016 Jan; 108():322-333. PubMed ID: 26698536
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery of novel pyrrolo-pyridine/pyrimidine derivatives bearing pyridazinone moiety as c-Met kinase inhibitors.
    Wang LX; Liu X; Xu S; Tang Q; Duan Y; Xiao Z; Zhi J; Jiang L; Zheng P; Zhu W
    Eur J Med Chem; 2017 Dec; 141():538-551. PubMed ID: 29107421
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design, synthesis and biological evaluation of novel 4-phenoxy-6,7-disubstituted quinolines possessing (thio)semicarbazones as c-Met kinase inhibitors.
    Zhai X; Bao G; Wang L; Cheng M; Zhao M; Zhao S; Zhou H; Gong P
    Bioorg Med Chem; 2016 Mar; 24(6):1331-45. PubMed ID: 26897090
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery of substituted 6-pheny-3H-pyridazin-3-one derivatives as novel c-Met kinase inhibitors.
    Kang ST; Kim EY; Achary R; Jung H; Park CH; Yun CS; Hwang JY; Choi SU; Chae C; Lee CO; Kim HR; Ha JD; Ryu D; Cho SY
    Bioorg Med Chem Lett; 2014 Nov; 24(21):5093-7. PubMed ID: 25282552
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification and optimization of pyridazinones as potent and selective c-Met kinase inhibitors.
    Dorsch D; Schadt O; Stieber F; Meyring M; Grädler U; Bladt F; Friese-Hamim M; Knühl C; Pehl U; Blaukat A
    Bioorg Med Chem Lett; 2015 Apr; 25(7):1597-602. PubMed ID: 25736998
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Triazolopyridazine derivatives: Synthesis, cytotoxic evaluation, c-Met kinase activity and molecular docking.
    Ahmed EM; Khalil NA; Taher AT; Refaey RH; Nissan YM
    Bioorg Chem; 2019 Nov; 92():103272. PubMed ID: 31539742
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthesis and biological evaluation of novel 6,11-dihydro-5H-benzo[e]pyrimido- [5,4-b][1,4]diazepine derivatives as potential c-Met inhibitors.
    Huang D; Huang L; Zhang Q; Li J
    Eur J Med Chem; 2017 Nov; 140():212-228. PubMed ID: 28938137
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery of substituted pyrazol-4-yl pyridazinone derivatives as novel c-Met kinase inhibitors.
    Kim EY; Kang ST; Jung H; Park CH; Yun CS; Hwang JY; Byun BJ; Lee CO; Kim HR; Ha JD; Ryu DH; Cho SY
    Arch Pharm Res; 2016 Apr; 39(4):453-464. PubMed ID: 26753914
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enhancing the cellular anti-proliferation activity of pyridazinones as c-met inhibitors using docking analysis.
    Xing W; Ai J; Jin S; Shi Z; Peng X; Wang L; Ji Y; Lu D; Liu Y; Geng M; Hu Y
    Eur J Med Chem; 2015 May; 95():302-12. PubMed ID: 25827399
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery of [1,2,4]triazolo[3,4-b][1,3,4]thiadiazole derivatives as novel, potent and selective c-Met kinase inhibitors: Synthesis, SAR study, and biological activity.
    Zhang L; Zhao J; Zhang B; Lu T; Chen Y
    Eur J Med Chem; 2018 Apr; 150():809-816. PubMed ID: 29602036
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery of novel 7-azaindole derivatives bearing dihydropyridazine moiety as c-Met kinase inhibitors.
    Tang Q; Wang L; Duan Y; Wang W; Huang S; Zhi J; Jia S; Zhu W; Wang P; Luo R; Zheng P
    Eur J Med Chem; 2017 Jun; 133():97-106. PubMed ID: 28384549
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design, synthesis, and molecular modelling of pyridazinone and phthalazinone derivatives as protein kinases inhibitors.
    Elagawany M; Ibrahim MA; Ali Ahmed HE; El-Etrawy ASh; Ghiaty A; Abdel-Samii ZK; El-Feky SA; Bajorath J
    Bioorg Med Chem Lett; 2013 Apr; 23(7):2007-13. PubMed ID: 23453843
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery of novel 2-aminopyridine-3-carboxamides as c-Met kinase inhibitors.
    Zhang D; Ai J; Liang Z; Li C; Peng X; Ji Y; Jiang H; Geng M; Luo C; Liu H
    Bioorg Med Chem; 2012 Sep; 20(17):5169-80. PubMed ID: 22863529
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 2,7-naphthyridinone-based MET kinase inhibitors: A promising novel scaffold for antitumor drug development.
    Zhuo LS; Xu HC; Wang MS; Zhao XE; Ming ZH; Zhu XL; Huang W; Yang GF
    Eur J Med Chem; 2019 Sep; 178():705-714. PubMed ID: 31229873
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design, synthesis and structure-activity relationships of novel 4-phenoxyquinoline derivatives containing pyridazinone moiety as potential antitumor agents.
    Zhou S; Liao H; He C; Dou Y; Jiang M; Ren L; Zhao Y; Gong P
    Eur J Med Chem; 2014 Aug; 83():581-93. PubMed ID: 24996144
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SGX523 is an exquisitely selective, ATP-competitive inhibitor of the MET receptor tyrosine kinase with antitumor activity in vivo.
    Buchanan SG; Hendle J; Lee PS; Smith CR; Bounaud PY; Jessen KA; Tang CM; Huser NH; Felce JD; Froning KJ; Peterman MC; Aubol BE; Gessert SF; Sauder JM; Schwinn KD; Russell M; Rooney IA; Adams J; Leon BC; Do TH; Blaney JM; Sprengeler PA; Thompson DA; Smyth L; Pelletier LA; Atwell S; Holme K; Wasserman SR; Emtage S; Burley SK; Reich SH
    Mol Cancer Ther; 2009 Dec; 8(12):3181-90. PubMed ID: 19934279
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design and synthesis of triazolopyridazines substituted with methylisoquinolinone as selective c-Met kinase inhibitors.
    Ryu JW; Han SY; Yun JI; Choi SU; Jung H; Ha JD; Cho SY; Lee CO; Kang NS; Koh JS; Kim HR; Lee J
    Bioorg Med Chem Lett; 2011 Dec; 21(23):7185-8. PubMed ID: 22001029
    [TBL] [Abstract][Full Text] [Related]  

  • 18. EMD 1214063 and EMD 1204831 constitute a new class of potent and highly selective c-Met inhibitors.
    Bladt F; Faden B; Friese-Hamim M; Knuehl C; Wilm C; Fittschen C; Grädler U; Meyring M; Dorsch D; Jaehrling F; Pehl U; Stieber F; Schadt O; Blaukat A
    Clin Cancer Res; 2013 Jun; 19(11):2941-51. PubMed ID: 23553846
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design, synthesis and molecular modeling studies of new series of antitumor 1,2,4-triazines with potential c-Met kinase inhibitory activity.
    El-Wakil MH; Ashour HM; Saudi MN; Hassan AM; Labouta IM
    Bioorg Chem; 2018 Feb; 76():154-165. PubMed ID: 29175587
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design, synthesis and structure-activity relationships of novel biarylamine-based Met kinase inhibitors.
    Williams DK; Chen XT; Tarby C; Kaltenbach R; Cai ZW; Tokarski JS; An Y; Sack JS; Wautlet B; Gullo-Brown J; Henley BJ; Jeyaseelan R; Kellar K; Manne V; Trainor GL; Lombardo LJ; Fargnoli J; Borzilleri RM
    Bioorg Med Chem Lett; 2010 May; 20(9):2998-3002. PubMed ID: 20382527
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.